ClinicaliQ Trial Snapshot
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting • Phase III • Mental Health / Psychiatry • NCT06963021.
- Trial testing whether adding NBI-1065845 to existing depression treatment works better than placebo for improving symptoms.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression. Conditions: Major Depressive Disorder Interventions: NBI-1065845, Placebo Lead Sponsor: Neurocrine Biosciences Planned Enrollment: 200 participants